dydrogesterone
AssetSmall moleculeAlso 17ß-Estradiol/Dydrogesterone
Progestogen receptor agonist used in hormone replacement therapy
- Stage
- Approved
- Modality
- Small molecule
- Target
- PGR
- Indications
- 2
- Trials
- 26
- Developers
- 2
Indications
3No named disease
Approvedaccessdata.fda.gov7 Oct 2026
Menopause
Phase 3COMPLETEDNCT00145522clinicaltrials.gov7 Oct 2026
Recurrent miscarriage
Phase 3COMPLETEDNCT00193674clinicaltrials.gov7 Oct 2026
- Targets and what it contains1
- Owner and partners2
- Trials26
- Evidence for its targets2
- Competitors9
Every asset’s record: target, stage, trials and the evidence behind it.
See ProUpdated 7 Oct 2026 · 5 sources